

# Candriam Sustainable Equity Japan

#### Market overview

The Bank of Japan appears to be getting scrap yield-curve control and negative rates. Governor Kazuo Ueda's comments in January after the BOJ stood pat suggested the move may come sooner than later, a surprisingly robust retreat in the BOJ's dovish tone. On January 22, the Japanese stock market tested an all-time high as it rose to its highest level in 33 years. Japan indices closed the month fairly flat [TPX +7.8%, NKY +8.4%].

## **Fund performance**

In January, the fund returned 7.93%\*, underperforming its benchmark by 55bp. The MSCI Japan NR ended the month up by 8.47%\*\*.

### Sector level

From a sector perspective, our stock selection detracted (-39bp) while allocation had a negligible impact on performance (-6bp). Our stock selection in Industrials (-106bp) and Financials (-18bp) underperformed. Our selection in Materials (32bp) and Information Technology (29bp) on the other hand, generated relative gains.

## Stock specific

With a positive contribution of 15bp, the overweight of **CAPCOM CO LTD** (Communication Services) was the main contributor to relative performance. With a negative contribution of 15bp, the overweight of **BAYCURRENT CONSULTING INC** (Industrials) was the main detractor from relative performance. In terms of absolute performance, our positions in **CAPCOM CO LTD** and **ADVANTEST CORP** (Information Technology) were the standout gainers, rising by 23.9% and 21.4% respectively. Our positions in **BAYCURRENT CONSULTING INC** and **MONOTARO CO LTD** (Industrials) were down 30.0% and 9.0% respectively.

## Portfolio activity

In January, we introduced the two enterprises located in Japan, **TDK CORP** (Information Technology) and **SUMITOMO CHEMICAL CO LTD** (Materials) to our portfolio (+1.1% and +0.4% respectively). We also increased the positions of the Japanese companies, **DAIICHI SANKYO CO LTD** and **CHUGAI PHARMACEUTICAL CO LTD**, both operating in the Health care sector as well as **TOKYO ELECTRON LTD** (Information Technology), from 0.8% to 2.3%, 1.2% to 1.6% and from 2.5% to 3.1% respectively. We sold our positions in the three Japanese enterprises, **ASTELLAS PHARMA INC** (Health Care), **T&D HOLDINGS INC** (Financials) and **KOBE STEEL LTD** (Materials) (-1.1%, -0.5% and -0.4% respectively). We also reduced the portfolio weights of the three Japanese corporations, **ADVANTEST CORP**, **YASKAWA ELECTRIC CORP** (Industrials) and **YAKULT HONSHA CO LTD** (Consumer Staples), from 0.7% to 0.3%, 1.4% to 0.8% and from 1.1% to 0.6% respectively.

### **Fund outlook**

We see a clear trend towards a more sustainable world. Authorities around the world are taking the lead by changing



<sup>\*</sup> net of fees in JPY terms

<sup>\*\*</sup> net return in JPY terms

#### MONTHLY FUND COMMENT

January 2024



regulations. Companies are taking active decisions by adjusting their business models to achieve a better ESG footprint. Consumers are taking ESG criteria into account when buying products and services, and investors are doing the same when evaluating alternatives to invest their wealth. In light of this trend, it is essential to take into account ESG criteria when making investment decisions. The objective of this strategy is to invest in companies that score well on both ESG and financial criteria. We believe that this type of company is well positioned to outperform the market in the long run.

This marketing communication is provided for information purposes only, it does not constitute an offer to buy or sell financial instruments, nor does it represent an investment recommendation or confirm any kind of transaction, except where expressly agreed. Although Candriam selects carefully the data and sources within this document, errors or omissions cannot be excluded a priori. Candriam cannot be held liable for any direct or indirect losses as a result of the use of this document. The intellectual property rights of Candriam must be respected at all times, contents of this document may not be reproduced without prior written approval.

Warning: Past performance of a given financial instrument or index or an investment service or strategy, or simulations of past performance, or forecasts of future performance does not predict future returns. Gross performances may be impacted by commissions, fees and other expenses. Performances expressed in a currency other than that of the investor's country of residence are subject to exchange rate fluctuations, with a negative or positive impact on gains. If the present document refers to a specific tax treatment, such information depends on the individual situation of each investor and may change In respect to money market funds, please be aware that an investment in a fund is different from an investment in deposits and that the investment's principal is capable of fluctuation. The fund does not rely on external support for guaranteeing its liquidity or stabilizing its NAV per unit or share. The risk of loss of the principal is borne by the investor.

Candriam consistently recommends investors to consult via our website www.candriam.com the key information document, prospectus, and all other relevant information prior to investing in one of our funds, including the net asset value ("NAV") of the funds. Investor rights and complaints procedure, are accessible on Candriam's dedicated regulatory webpages https://www.candriam.com/en/professional/legal-and-disclaimer-candriam/regulatory-information/. This information is available either in English or in local languages for each country where the fund's marketing is approved. According to the applicable laws

and regulations, Candriam may decide to terminate the arrangements made for the marketing of a relevant fund at any time.

Information on sustainability-related aspects: the information on sustainability-related aspects contained in this communication are available on Candriam webpage https://www.candriam.com/en/professional/market-insights/sfdr/. The decision to invest in the promoted product should take into account all the characteristics or objectives of the promoted product as described in its prospectus, or in the information documents which are to be disclosed to investors in accordance with the applicable law.

Notice to investors in Switzerland: The information provided herein does not constitute an offer of financial instruments in Switzerland pursuant to the Swiss Financial Services Act ("FinSA") and its implementing ordinance. This is solely an advertisement pursuant to FinSA and its implementing ordinance for financial instruments.

Swiss representative: CACEIS (Switzerland) SA, Route de Signy 35, CH-1260 Nyon. The legal documents as well as the latest annual and semi-annual financial reports, if any, of the investment funds may

Swiss paying agent: CACEIS Bank, Paris, succursale de Nyon/Suisse, Route de Signy, 35, CH-1260 Nyon. Place of performance: Route de Signy 35, CH-1260 Nyon. Place of jurisdiction: Route de Signy 35,

Specific information for investors in France: the appointed representative and paying agent in France is CACEIS Bank, Luxembourg Branch, sis 1-3, place Valhubert, 75013 Paris, France. The prospectus, the key investor information, the articles of association or as applicable the management rules as well as the annual and semi-annual reports, each in paper form, are made available free of charge at the representative and paying agent in France.

Specific information for investors in Spain: Candriam Sucursal en España has its registered office at C/ Pedro Teixeira, 8, Edif. Iberia Mart I, planta 4, 28020 Madrid and is registered with the Comisión Nacional del Mercado de Valores (CNMV) as an European Economic Area management company with a branch. CNMV: 1493

